{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:14:07Z","timestamp":1778753647093,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300162"],"award-info":[{"award-number":["82300162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270145"],"award-info":[{"award-number":["82270145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2510500"],"award-info":[{"award-number":["2024YFC2510500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2022-I2M-2-003, 2021-I2M-1-073"],"award-info":[{"award-number":["2022-I2M-2-003, 2021-I2M-1-073"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07023-y","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:50:07Z","timestamp":1776736207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome"],"prefix":"10.1007","volume":"105","author":[{"given":"Zhen","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuechen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhexiang","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neng","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meili","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"8","key":"7023_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G (2023) Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(8):1307\u20131325","journal-title":"Am J Hematol"},{"issue":"1","key":"7023_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00402-5","volume":"8","author":"H Li","year":"2022","unstructured":"Li H, Hu F, Gale RP, Sekeres MA, Liang Y (2022) Myelodysplastic syndromes. Nat Rev Dis Primers 8(1):74","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"7023_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA, Taylor J (2022) Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA 328(9):872\u2013880","journal-title":"JAMA"},{"issue":"1","key":"7023_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/hematology.2020000127","volume":"2020","author":"HE Carraway","year":"2020","unstructured":"Carraway HE, Saygin C (2020) Therapy for lower-risk MDS. Hematology 2020(1):426\u2013433","journal-title":"Hematology"},{"issue":"1","key":"7023_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-22-1457","volume":"29","author":"JD Gonzalez-Lugo","year":"2023","unstructured":"Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P et al (2023) Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial. Clin Cancer Res 29(1):60\u201366","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7023_CR6","first-page":"2157","volume":"109","author":"AG Jain","year":"2024","unstructured":"Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S et al (2024) Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica 109(7):2157\u20132164","journal-title":"Haematologica"},{"issue":"24","key":"7023_CR7","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1002\/cncr.26173","volume":"117","author":"JR Gonzalez-Porras","year":"2011","unstructured":"Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F et al (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 117(24):5529\u20135537","journal-title":"Cancer"},{"issue":"10","key":"7023_CR8","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00277-021-04608-7","volume":"100","author":"J Strapatsas","year":"2021","unstructured":"Strapatsas J, Barbulescu EC, Lauseker M, Kaivers J, Hildebrandt B, Nachtkamp K et al (2021) Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients. Ann Hematol 100(10):2575\u20132584","journal-title":"Ann Hematol"},{"issue":"28","key":"7023_CR9","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1200\/JCO.22.02699","volume":"41","author":"EN Oliva","year":"2023","unstructured":"Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V et al (2023) Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). J Clin Oncol 41(28):4486\u20134496","journal-title":"J Clin Oncol"},{"issue":"28","key":"7023_CR10","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1200\/JCO.23.01141","volume":"41","author":"AG Kulasekararaj","year":"2023","unstructured":"Kulasekararaj AG, Trikha R (2023) Eltrombopag in lower-risk myelodysplastic syndrome: revival of its use in thrombocytopenia. J Clin Oncol 41(28):4465\u20134468","journal-title":"J Clin Oncol"},{"issue":"4","key":"7023_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/ejh.14156","volume":"112","author":"A Mo","year":"2024","unstructured":"Mo A, Weinkove R, Wood EM, Shortt J, Johnston A, McQuilten ZK, Australasian Leukaemia and Lymphoma Group Supportive Care Scientific Working Party (2024) Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: a clinical practice survey. Eur J Haematol 112(4):621\u2013626","journal-title":"Eur J Haematol"},{"issue":"2","key":"7023_CR12","first-page":"330","volume":"110","author":"AMA Merz","year":"2025","unstructured":"Merz AMA, Platzbecker U (2025) Treatment of lower-risk myelodysplastic syndromes. Haematologica 110(2):330\u2013338","journal-title":"Haematologica"},{"issue":"6","key":"7023_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/bjh.14792","volume":"178","author":"P Fenaux","year":"2017","unstructured":"Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA et al (2017) Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol 178(6):906\u2013913","journal-title":"Br J Haematol"},{"issue":"2","key":"7023_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjh.17538","volume":"194","author":"M Mittelman","year":"2021","unstructured":"Mittelman M, Oster HS (2021) Thrombocytopenia in myelodysplastic syndromes: time to lift the embargo on thrombomimetics? Br J Haematol 194(2):231\u2013233","journal-title":"Br J Haematol"},{"issue":"3","key":"7023_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","volume":"28","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D et al (2010) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28(3):437\u2013444","journal-title":"J Clin Oncol"},{"issue":"3","key":"7023_CR16","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","volume":"5","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A et al (2018) Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol 5(3):e117\u2013e126","journal-title":"Lancet Haematol"},{"issue":"6","key":"7023_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1053\/j.seminhematol.2024.08.001","volume":"61","author":"TM Getz","year":"2024","unstructured":"Getz TM, Bewersdorf JP, Kewan T, Stempel JM, Bidikian A, Shallis RM et al (2024) Beyond HMAs: Novel Targets and Therapeutic Approaches. Semin Hematol 61(6):358\u2013369","journal-title":"Semin Hematol"},{"issue":"4","key":"7023_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000867","volume":"7","author":"M Riva","year":"2023","unstructured":"Riva M, Bosi A, Rizzo L, Mazzon F, Ferrari S, Lussana F et al (2023) Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an \u201cOld-fashioned\u201d Drug be Effective? Hemasphere 7(4):e867","journal-title":"Hemasphere"},{"issue":"1","key":"7023_CR19","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1111\/bjh.16121","volume":"187","author":"EJ Choi","year":"2019","unstructured":"Choi EJ, Lee JH, Park HS, Lee JH, Seol M, Lee YS et al (2019) Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study. Br J Haematol 187(1):e4\u2013e7","journal-title":"Br J Haematol"},{"key":"7023_CR20","doi-asserted-by":"crossref","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, International Vidaza High-Risk MDS Survival Study Group et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223\u201332","DOI":"10.1016\/S1470-2045(09)70003-8"},{"issue":"13","key":"7023_CR21","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","volume":"130","author":"E Jabbour","year":"2017","unstructured":"Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W et al (2017) Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN. Blood 130(13):1514\u20131522","journal-title":"Blood"},{"issue":"10","key":"7023_CR22","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.7150\/jca.56207","volume":"12","author":"L Ye","year":"2021","unstructured":"Ye L, Mei C, Ren Y, Zhou X, Ma L, Xu W et al (2021) Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. J Cancer 12(10):2975\u20132981","journal-title":"J Cancer"},{"issue":"5","key":"7023_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11864-023-01062-7","volume":"24","author":"C Wang","year":"2023","unstructured":"Wang C, Sallman DA (2023) Current therapeutic landscape in lower risk myelodysplastic syndromes. Curr Treat Options Oncol 24(5):387\u2013408","journal-title":"Curr Treat Options Oncol"},{"issue":"27","key":"7023_CR24","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2217\/fon-2023-0454","volume":"19","author":"T Badar","year":"2023","unstructured":"Badar T, Madanat YF, Zeidan AM (2023) Updates on risk stratification and management of lower-risk myelodysplastic syndromes\/neoplasms. Future Oncol 19(27):1877\u20131889","journal-title":"Future Oncol"},{"issue":"1","key":"7023_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56642-1","volume":"10","author":"BH Lee","year":"2020","unstructured":"Lee BH, Kang KW, Jeon MJ, Yu ES, Kim DS, Choi H et al (2020) Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. Sci Rep 10(1):39","journal-title":"Sci Rep"},{"issue":"3","key":"7023_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41375-023-01819-x","volume":"37","author":"K Liapis","year":"2023","unstructured":"Liapis K, Papadopoulos V, Pontikoglou C, Vrachiolias G, Stavroulaki E, Kourakli A et al (2023) Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries. Leukemia 37(3):708\u2013711","journal-title":"Leukemia"},{"issue":"12","key":"7023_CR27","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/ajh.25646","volume":"94","author":"H Zhou","year":"2019","unstructured":"Zhou H, Qin P, Liu Q, Yuan C, Hao Y, Zhang H et al (2019) A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia. Am J Hematol 94(12):1374\u20131381","journal-title":"Am J Hematol"},{"key":"7023_CR28","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. 2022 The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36:1703\u201319."},{"key":"7023_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951","journal-title":"Blood"},{"key":"7023_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425","journal-title":"Blood"},{"issue":"12","key":"7023_CR31","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454\u20132465","journal-title":"Blood"},{"issue":"7","key":"7023_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y et al (2022) Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence 1(7):EVIDoa2200008","journal-title":"NEJM Evidence"},{"issue":"25","key":"7023_CR33","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","volume":"132","author":"M Dickinson","year":"2018","unstructured":"Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO et al (2018) Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood 132(25):2629\u20132638","journal-title":"Blood"},{"issue":"3","key":"7023_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000479485","volume":"138","author":"H Li","year":"2017","unstructured":"Li H, Wang L, Wu Y, Su L, Zhao H, Zhang Y et al (2017) Very-low-dose decitabine is effective in treating intermediate- or high-risk myelodysplastic syndrome. Acta Haematol 138(3):168\u2013174","journal-title":"Acta Haematol"},{"issue":"8","key":"7023_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/17474086.2017.1346470","volume":"10","author":"KE Lindblad","year":"2017","unstructured":"Lindblad KE, Goswami M, Hourigan CS, Oetjen KA (2017) Immunological effects of hypomethylating agents. Expert Rev Hematol 10(8):745\u2013752","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"7023_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.630693","volume":"17","author":"P Han","year":"2021","unstructured":"Han P, Yu T, Hou Y, Zhao Y, Liu Y, Sun Y et al (2021) Low-dose decitabine inhibits cytotoxic T lymphocytes-mediated platelet destruction via modulating PD-1 methylation in immune thrombocytopenia. Front Immunol 17(12):630693","journal-title":"Front Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07023-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:57Z","timestamp":1778750577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07023-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7023"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07023-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study utilizes data from the National Longitudinal Cohort of Hematological Diseases in China (NICHE, NCT04645199). The trial was conducted in compliance with the principles outlined in the Declaration of Helsinki and received approval from the ethics committees at the Institute of Hematology and Blood Diseases Hospital (approval no. IIT2021029-EC-1). Informed written consent was obtained from all participating patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"258"}}